Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Rani Therapeutics Holdings Inc (NASDAQ: RANI) was $1.34 for the day, down -8.84% from the previous closing price of $1.47. In other words, the price has decreased by -$8.84 from its previous closing price. On the day, 3.33 million shares were traded. RANI stock price reached its highest trading level at $1.53 during the session, while it also had its lowest trading level at $1.34.
Ratios:
Our analysis of RANI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.26 and its Current Ratio is at 0.26.
Upgrades & Downgrades
In the most recent recommendation for this company, Oppenheimer on August 02, 2024, initiated with a Outperform rating and assigned the stock a target price of $17.
On June 14, 2024, Maxim Group started tracking the stock assigning a Buy rating and target price of $15.
On June 13, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $10.Rodman & Renshaw initiated its Buy rating on June 13, 2024, with a $10 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 23 ’25 when IMRAN MIR A bought 2,083,334 shares for $0.60 per share. The transaction valued at 1,260,417 led to the insider holds 2,083,334 shares of the business.
South Cone Investments Limited sold 4,000,000 shares of RANI for $11,074,000 on Oct 21 ’25. The 10% Owner now owns 2,379,194 shares after completing the transaction at $2.77 per share. On Oct 20 ’25, another insider, South Cone Investments Limited, who serves as the 10% Owner of the company, sold 1,923,000 shares for $2.41 each. As a result, the insider received 4,637,314 and left with 6,379,194 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RANI now has a Market Capitalization of 164345024 and an Enterprise Value of 140002240. For the stock, the TTM Price-to-Sale (P/S) ratio is 135.70. Its current Enterprise Value per Revenue stands at 116.669 whereas that against EBITDA is -3.497.
Stock Price History:
The Beta on a monthly basis for RANI is 0.42, which has changed by -0.0754717 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, RANI has reached a high of $3.87, while it has fallen to a 52-week low of $0.39. The 50-Day Moving Average of the stock is -14.40%, while the 200-Day Moving Average is calculated to be 36.98%.
Shares Statistics:
RANI traded an average of 17.95M shares per day over the past three months and 2520780 shares per day over the past ten days. A total of 97.55M shares are outstanding, with a floating share count of 60.42M. Insiders hold about 8.02% of the company’s shares, while institutions hold 12.13% stake in the company. Shares short for RANI as of 1764288000 were 10601934 with a Short Ratio of 0.59, compared to 1761868800 on 4968738. Therefore, it implies a Short% of Shares Outstanding of 10601934 and a Short% of Float of 11.21.
Earnings Estimates
The dynamic stock of Rani Therapeutics Holdings Inc (RANI) is currently being evaluated by a team of 3.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.14 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.35 and -$0.58 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.32, with 3.0 analysts recommending between -$0.18 and -$0.59.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for RANI’s current fiscal year. The highest revenue estimate was $10.17M, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $5.19M. In the same quarter a year ago, actual revenue was $1.03M
